	US 12,465,607 B2
	ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases
Hesso Farhan, Oslo (NO); Ludvig Munthe, Fjellhamar (NO); Kjetil Tasken, Rykkinn (NO); Sigrid Skanland, Oslo (NO); Mariaserena Giliberto, Oslo (NO); Fredrik Hellem Schjesvold, Jar (NO); Christoph Driessen, St. Gallen (CH); Lenka Besse, St. Gallen (CH); and Andrej Besse, St. Gallen (CH)
Assigned to UNIVERSITETET I OSLO, Oslo (NO)
Appl. No. 17/772,192
Filed by UNIVERSITETET I OSLO, Oslo (NO)
PCT Filed Mar. 12, 2020, PCT No. PCT/EP2020/056698 § 371(c)(1), (2) Date Apr. 27, 2022, PCT Pub. No. WO2021/083555, PCT Pub. Date May 6, 2021.
Claims priority of application No. 1915618 (GB), filed on Oct. 28, 2019.
Prior Publication US 2022/0401444 A1, Dec. 22, 2022
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61P 35/02 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61P 35/02 (2018.01)]

12 Claims

1. A method of treating a subject suffering from:

(i) an anaplastic lymphoma kinase (ALK)-negative and leukocyte tyrosine kinase (LTK)-positive (ALK^NegLTK^Pos) cancer selected from multiple myeloma or chronic lymphocytic leukaemia; or

ii) a plasma cell-mediated disease mediated by ALK^NegLTK^PosPos plasma cells, selected from an autoimmune disease or graft versus host disease (GVHD),

wherein said cancer or plasma cell-mediated disease is characterised by antibody hypersecretion by said ALK^NegLTK^Poscancer or plasma cells,

said method comprising administering to said subject a pharmaceutically-effective dose of an ALK inhibitor selected from ceritinib, brigatinib, crizotinib, ensartinib, alectinib and entrectinib.